Compare W & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | W | PRAX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.6B |
| IPO Year | 2014 | 2020 |
| Metric | W | PRAX |
|---|---|---|
| Price | $79.58 | $305.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 15 |
| Target Price | $105.82 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 3.7M | 306.4K |
| Earning Date | 05-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $6.00 | $6,395.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.41 | $26.70 |
| 52 Week High | $119.98 | $354.87 |
| Indicator | W | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 43.82 |
| Support Level | $70.59 | $290.36 |
| Resistance Level | $82.72 | $322.32 |
| Average True Range (ATR) | 4.17 | 16.80 |
| MACD | 1.28 | -3.80 |
| Stochastic Oscillator | 69.50 | 22.51 |
Wayfair engages in e-commerce in the United States (88% of 2025 sales), Canada, the United Kingdom, and Ireland. It's also embarked on expansion into the brick-and-mortar landscape, with 12 stores (excluding outlets) between the AllModern, Birch Lane, Joss & Main, and Wayfair banners. At the end of 2025, the firm offered more than 40 million products from more than 20,000 suppliers under the brands Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Its offerings include furniture, everyday and seasonal decor, decorative accents, housewares, as well as advertising and logistics services. Wayfair was founded in 2002 and began trading publicly in 2014.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.